Psychiatry and Neurology, Neurology with Special Qualifications in Child Neurology · Little Rock, AR
NPI
1144596412
Since 2012
Specialty
Psychiatry and Neurology, Neurology with Special Qualifications in Child Neurology
Code 2084N0402X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
1 Childrens Way # 512-15
Little Rock, AR, 72202
Phone (501) 364-5281
Groups this clinician bills Medicare through
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$344K
17 prescriptions
Company payments, 2025
$193K
From 15 companies
Medicare prescription drug claims, 2024
In 2024, the drug Aravindhan Veerapandiyan prescribed most often to Medicare patients was Emflaza (Deflazacort), with 11 prescriptions and refills. In total Aravindhan Veerapandiyan wrote 17 Medicare prescriptions that cost $344K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-06-18.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Emflaza Deflazacort | 11 | 11 | Under 11 | $339K |
Brand drugs: 12 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Aravindhan Veerapandiyan $193K ($188K in general payments such as food, travel and fees and $4,930 for research) from 15 companies. The largest payer was Sarepta Therapeutics, Inc. with $141K.
| Company | Payments | Amount |
|---|---|---|
| Sarepta Therapeutics, Inc. SRPT | 35 | $141K |
| ITF Therapeutics LLC | 12 | $17K |
| F. Hoffmann-La Roche AG ROG.SW | 8 | $13K |
| Biogen, Inc. BIIB | 1 | $8,563 |
| Pfizer Inc. PFE | 2 | $3,530 |
| GRT US Holding, Inc. | 2 | $2,850 |
| UCB, Inc. UCB.BR | 2 | $2,699 |
| Catalyst Pharmaceuticals, Inc. CPRX | 8 | $2,477 |
| Mesoblast, Inc. MESO | 1 | $1,500 |
| PTC Therapeutics, Inc. PTCT | 1 | $128 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.